Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression
Understanding of molecular events in cancer requires proteome-level characterisation. Here, proteome profiling of patient samples representing primary and progressed prostate cancer enables the authors to identify pathway alterations that are not reflected at the genomic and transcriptomic levels.
Guardado en:
Autores principales: | Leena Latonen, Ebrahim Afyounian, Antti Jylhä, Janika Nättinen, Ulla Aapola, Matti Annala, Kati K. Kivinummi, Teuvo T. L. Tammela, Roger W. Beuerman, Hannu Uusitalo, Matti Nykter, Tapio Visakorpi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/61f749925834414ebb92c52acbc5d9a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparative proteomic analysis of human embryonic stem cell-derived and primary human retinal pigment epithelium
por: Heidi Hongisto, et al.
Publicado: (2017) -
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
por: Sanna Siltanen, et al.
Publicado: (2011) -
Transcriptional analysis reveals gender-specific changes in the aging of the human immune system.
por: Saara Marttila, et al.
Publicado: (2013) -
Leukemia prediction using sparse logistic regression.
por: Tapio Manninen, et al.
Publicado: (2013) -
Sivistys ja demokratia
por: Antti Moilanen, et al.
Publicado: (2021)